Medicine Information

Carboplatin-Phares

Name: Carboplatin-Phares
Brand: Carboplatin-Phares
Rating: 4.5 (117 reviews)

Injection10 mgAntineoplastic agent (Platinum compound)ATC: L01XA02

Generic Name

carboplatin-phares-10-mg-injection

Manufacturer

Phares Pharmaceuticals

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
carboplatin phares 10 mg injection	৳ 3,360.00	N/A

Description

Overview of the medicine

Carboplatin is a platinum-based chemotherapy drug used to treat various types of cancer by interfering with DNA replication and repair in cancer cells.

Uses & Indications

Advanced ovarian carcinoma (first-line and second-line therapy)

Small cell lung cancer

Non-small cell lung cancer

Head and neck cancers

Brain tumors

Dosage

Adults

Dosage is highly individualized based on body surface area (BSA) or Area Under the Curve (AUC) using the Calvert formula, typically 300-400 mg/m² IV every 4 weeks, or AUC 5-7 mg/mL·min.

Elderly

Similar to adults, but with careful monitoring of renal function and complete blood counts due to potential age-related decline in kidney function.

Renal_impairment

Dose reduction is required for patients with creatinine clearance < 60 mL/min. Dosing based on AUC should be adjusted according to renal function.

How to Take

Administered by intravenous (IV) infusion over 15-60 minutes, usually diluted in 5% Dextrose Injection or 0.9% Sodium Chloride Injection.

Mechanism of Action

Carboplatin works by forming DNA adducts and inter- and intra-strand cross-links, which ultimately leads to inhibition of DNA synthesis, function, and repair, resulting in apoptosis of cancer cells.

Pharmacokinetics

Onset

Rapid distribution with peak plasma platinum concentrations achieved shortly after infusion.

Excretion

Primarily excreted unchanged in the urine (60-70% within 24 hours).

Half life

Initial half-life of 2-6 hours, with a terminal elimination half-life of 24-48 hours for ultrafilterable platinum.

Absorption

Rapid and complete absorption after intravenous administration (100% bioavailability).

Metabolism

Undergoes non-enzymatic conversion in plasma; platinum binds extensively to plasma proteins and DNA.

Side Effects

Contraindications

History of severe hypersensitivity reactions to carboplatin or other platinum-containing compounds
Severe bone marrow depression
Pre-existing severe renal impairment
Pregnancy and lactation

Drug Interactions

Myelosuppressive agents

Potentiated myelosuppression, requiring careful monitoring and potential dose adjustments.

Ototoxic drugs (e.g., loop diuretics)

Increased risk of ototoxicity.

Nephrotoxic drugs (e.g., aminoglycosides)

Increased risk of renal toxicity and ototoxicity.

Storage

Store intact vials at controlled room temperature (20-25°C), protect from light. Do not freeze. Diluted solutions should be used within 8-24 hours depending on the diluent.

Overdose

Symptoms of overdose include severe myelosuppression, renal and hepatic failure, and profound ototoxicity. Management is supportive, including blood transfusions, granulocyte colony-stimulating factors, and monitoring of vital signs and organ function.

Pregnancy & Lactation

Carboplatin is contraindicated in pregnancy due to its genotoxic, embryotoxic, and teratogenic potential. It is also advised against during lactation as it is unknown if carboplatin or its metabolites are excreted in human milk.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 mg/5 mL vial50 mg/25 mL vial150 mg/15 mL vial450 mg/45 mL vial

Shelf Life

Typically 2-3 years when stored unopened under recommended conditions. Refer to specific product labeling for exact duration.

Availability

Hospitals and specialized cancer treatment centers

Approval Status

Approved by regulatory authorities

Patent Status

Generic available (off-patent)

WHO Essential Medicine

Yes

Clinical Trials

Ongoing clinical trials continue to explore new indications, optimal dosing regimens, combination therapies, and strategies to mitigate resistance and adverse effects for carboplatin.

Lab Monitoring

Complete blood count (CBC) with differential (before each cycle and regularly thereafter)
Renal function tests (serum creatinine, creatinine clearance, GFR) before each cycle
Liver function tests
Electrolyte levels (magnesium, sodium, potassium)
Audiometric evaluations (for high-risk patients or those reporting symptoms)

Doctor Notes

Emphasize meticulous monitoring of CBC with differential before each cycle, with dose adjustments based on nadir counts and renal function (Calvert formula).
Premedication for nausea and vomiting is crucial. Be vigilant for hypersensitivity reactions, especially after multiple cycles.
Ensure adequate hydration before and after administration.

Patient Guidelines

Report any signs of infection (fever, chills), unusual bleeding or bruising, severe nausea/vomiting, or allergic reactions immediately.
Maintain adequate hydration as advised by your doctor.
Avoid contact with people who are sick or have infections.

Missed Dose Advice

Carboplatin is administered by a healthcare professional in a clinical setting. If a dose is missed, it should be reported immediately to the treating physician, and the treatment schedule will be adjusted as necessary.

Driving Precautions

Carboplatin may cause fatigue, nausea, or visual disturbances. Patients should be advised not to drive or operate machinery if they experience these side effects.